The Crohn's & Colitis Foundation of America Company Profile

08:55 EDT 17th March 2018 | BioPortfolio

News Articles [753 Associated News Articles listed on BioPortfolio]

Obesity increases risk for surgery in patients with ulcerative colitis

Amanda M. LynnPatients with ulcerative colitis who have a higher BMI are at increased risk for bowel resection, according to research presented at the Crohn’s & Colitis Congress.Amanda M. Lynn, MD, ...

Genetic Mutation Linked to Crohn's and Parkinson's Diseases

The inflammatory bowel diseases (IBD) are composed of two major subtypes, Crohn’s disease (CD) and ulcerative colitis (UC), which are...

K’NEX® President & CEO, Michael Araten and his wife, Ellen, To Be Honored By The Crohn’s & Colitis Foundation

Philadelphia/Delaware Valley Chapter to Present the Couple with the Founders Award During October 21st Renaissance Ball HATFIELD, Pa. (PRWEB) October 12, 2017 K’NEX, the construction toy company wh...

Janssen to Codevelop Theravance's TD-1473 in $1B+ Collaboration

Johnson & Johnson’s Janssen Biotech will codevelop Theravance’s TD-1473 and related backup compounds for inflammatory intestinal diseases, including ulcerative colitis and Crohn's disease,...

Changing gut bacteria in Crohn’s disease

A single enzyme altered the mix of bacteria in the guts of mice and led to inflammatory bowel disease. The study suggests a potential treatment target for diseases such as Crohn’s disease and ulcera...

Qu Biologics invited to present research data at inaugural Crohn’s and Colitis Congress

VANCOUVER, British Columbia, Dec. 19, 2017 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of immunotherapie...

J&J takes option on Theravance’s JAK drug in $1bn deal

TD-1473 has potential treating ulcerative colitis, Crohn’s and IBD patients

BRIEF—Entyvio analyses show improvements in ulcerative colitis or Crohn’s disease

Takeda Pharmaceutical has announced the presentation of data suggesting early symptomatic improvement…

Drugs and Medications [765 Associated Drugs and Medications listed on BioPortfolio]

Shiseido perfect refining foundation [SHISEIDO AMERICA INC.]

SHISEIDO Perfect Refining Foundation

Shiseido white lucent brightening spot-control foundation (refill) [SHISEIDO AMERICA INC.]

SHISEIDO WHITE LUCENT Brightening Spot-Control Foundation (Refill)

Esika [Ventura Corporation (San Juan, P.R)]

ēsika 3-in-1 Pro Make Up Foundation SPF 20

Sheer cover mineral foundation [Guthy-Renker LLC]

Sheer Cover Mineral Foundation SPF-15

Cle de peau beaute silky foundation i [SHISEIDO CO., LTD.]

CPB Silky Cream Foundation I

PubMed Articles [1367 Associated PubMed Articles listed on BioPortfolio]

Plasma microRNA Profile Differentiates Crohn's Colitis From Ulcerative Colitis.

Inflammatory bowel disease (IBD) is commonly divided into 2 entities: Crohn's disease (CD) and ulcerative colitis (UC). Differentiating between these entities when dealing with IBD confined to the col...

2nd N-ECCO Consensus Statements on the European Nursing Roles in Caring for Patients with Crohn's Disease or Ulcerative Colitis.

Corrigendum: Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease.

The unfinished symphony: golimumab therapy for anti-TNF refractory Crohn's disease.

Golimumab is approved for the treatment of moderate-to-severely active ulcerative colitis. However, there have been no formal trials to date to assess its utility in Crohn's disease (CD). Our aim was ...

Determinants of Reduced Genetic Capacity for Butyrate Synthesis by the Gut Microbiome in Crohn's Disease and Ulcerative Colitis.

Alterations in short chain fatty acid metabolism, particularly butyrate, have been reported in inflammatory bowel disease, but results have been conflicting because of small study numbers and failure ...

Clinical Trials [1335 Associated Clinical Trials listed on BioPortfolio]

Risk Factors for Microscopic Colitis

Microscopic colitis is a common cause of watery diarrhea, particularly in the elderly. Although the incidence is comparable to ulcerative colitis and Crohn's disease, the etiology is unkno...

A Phase 2, Randomized, Double-Blind, Dose-Ranging Study With Vedolizumab IV in Pediatric Participants With Ulcerative Colitis or Crohn's Disease

The purpose of this study is to evaluate vedolizumab pharmacokinetics (PK), safety and tolerability in pediatric participants with moderately to severely active ulcerative colitis or Crohn...

Extended Access Program of Vedolizumab IV in Ulcerative Colitis and Crohn's Disease

The purpose of this study is to monitor ongoing safety in subjects with ulcerative colitis (UC) and Crohn's disease (CD) and to provide access to vedolizumab for qualifying subjects who, i...

Postmarketing Vedolizumab Milk-Only Lactation Study in Lactating Women With Active Ulcerative Colitis or Crohn's Disease

The purpose of this study is to assess the concentration of vedolizumab in breast milk of lactating women with active ulcerative colitis (UC) or Crohn's disease (CD) who are receiving vedo...

Effect of Iron and Vitamin E Supplementation on Disease Activity in Patients With Either Crohn's Disease or Ulcerative Colitis

Hypothesis:In patients with ulcerative colitis and Crohn's disease diagnosed with mild or moderate anaemia: 1. iron supplementation will increase disease activity and oxidative stress ...

Companies [2260 Associated Companies listed on BioPortfolio]

RMEI Medical Education (RMEI) and Crohn's & Colitis Foundation

The Crohn's & Colitis Foundation (the Foundation) is the largest non-profit, voluntary, health organization dedicated to finding cures for inflammatory bowel diseases (IBD). The F...

The Crohn's & Colitis Foundation of America

Crohns & Colitis Foundation of America

Crohn's disease, a chronic inflammatory disease of the gastrointestinal tract, affects approximately 500,000 Americans, including approximately 100,000 pediatric patients. The cause of Crohn's diseas...

Crohn's & Colitis Foundation of America

The Crohn's & Colitis Foundation of America is the largest non-profit, volunteer-driven organization dedicated to finding a cure for Crohn's disease and ulcerative colitis, and it ranks third among le...

Crohn'sAdvocate Program

Developed as a support and advocacy program for the half a million Americans affected by Crohn's disease, the Crohn'sAdvocate(TM) program was launched nearly a year ago by UCB. The program takes a 36...

More Information about "The Crohn's & Colitis Foundation of America" on BioPortfolio

We have published hundreds of The Crohn's & Colitis Foundation of America news stories on BioPortfolio along with dozens of The Crohn's & Colitis Foundation of America Clinical Trials and PubMed Articles about The Crohn's & Colitis Foundation of America for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of The Crohn's & Colitis Foundation of America Companies in our database. You can also find out about relevant The Crohn's & Colitis Foundation of America Drugs and Medications on this site too.

Quick Search


Corporate Database Quicklinks

Searches Linking to this Company Record